Premature ovarian insufficiency (POI) refers to a condition in which the ovarian functions cease before the age of 40, resulting in infertility. This has been a life sentence for many women, who have had to come to terms with the reality of their infertility and the lack of treatment options for the condition.
However, recent research has pointed to ovarian fibrosis, or the presence of excess fibrotic tissue in the ovaries, as a possible factor in the failure of the follicles to develop in women who have POI. The follicles in the ovary play a crucial role in the development of the eggs in women. However, the presence of fibrotic tissue in the ovary results in a rigid environment, which affects the development of the follicles. Antifibrotic drug shows promise for premature ovarian insufficiency | EurekAlert!
Interestingly, recent research has also pointed to the possibility of antifibrotic therapy, which has been used to treat fibrotic diseases in other parts of the body, to reverse the fibrotic process in the ovary and induce the development of the follicles. This has opened up the prospect of fertility treatments for women who have POI, in which the underlying tissue changes in the ovary could be targeted to induce fertility.
Could targeting fibrosis be the key to unlocking new fertility treatments in the future?
MBH/PS